window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biotech

  • Biotech,Drug discovery,Facilities and infrastructure,Research & Development,Technology and platforms

    FairJourney Bio opens cryo-EM facility in San Diego for antibody discovery

    FairJourney Bio has opened a cryo-EM structural biology facility in [...]

    April 17, 2026
  • Artificial Intelligence,Biotech,Drug Development,Drug discovery,Research & Development

    ProQR partners with Ginkgo Bioworks for AI-driven RNA editing development and forms advisory board

    ProQR Therapeutics has entered a collaboration with Ginkgo Bioworks to [...]

    April 9, 2026
  • Biotech,Funding,Genetic Diseases,Mergers & Acquisitions,Research & Development,RNA Therapeutics

    Circio raises NOK 250M in oversubscribed private placement to advance circRNA gene therapy platform

    Circio has raised NOK 250 million in a significantly oversubscribed [...]

    April 8, 2026
  • Biotech,Healthcare leadership,Movers & Shakers,Oncology,Pharmaceuticals and therapeutics,Research & Development

    Orano Med appoints Frederic Desdouits as CEO to advance targeted alpha therapy pipeline

    Orano has appointed Frederic Desdouits as chief executive officer of [...]

    April 8, 2026
  • Biotech,Clinical Development,Clinical Trials,Healthcare leadership,Immunology,Movers & Shakers

    Aravax adds allergy specialists to board as peanut therapy advances

    Aravax has appointed two senior industry figures to its board [...]

    April 8, 2026
  • Artificial Intelligence,Biotech,Research & Development,Technology and platforms

    Nanotube injector enables controlled cytoplasmic transfer between living cells

    Researchers in Japan have developed a nanotube-based system that enables [...]

    April 7, 2026
  • Biotech,Drug discovery,Healthcare leadership,Movers & Shakers,Research & Development,Startups and innovations,Technology and platforms

    Proxygen appoints Chiara Conti as chief scientific officer to support move into clinical-stage development

    Proxygen has appointed Chiara Conti as chief scientific officer, as [...]

    April 2, 2026
  • Biotech,Drug Delivery & Formulation,Drug Development,Partnerships & Funding,Pharmaceuticals and therapeutics

    Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes

    Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies [...]

    March 30, 2026
  • Biotech,Drug discovery,Research & Development,Technology and platforms

    Nuclera launches GPCR nanodisc panel to address membrane protein bottleneck in drug discovery

    Nuclera has launched a nanodisc panel designed to improve the [...]

    March 30, 2026
  • Biotech,Digital Health,Research & Development

    Ribbon CEO calls for faster adoption of AI and DNA synthesis to accelerate drug development

    The chief executive of Ribbon Biolabs has called for faster [...]

    March 27, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top